KR20230121831A - 인테그린 알파 11 베타 1에 대한 항체 - Google Patents

인테그린 알파 11 베타 1에 대한 항체 Download PDF

Info

Publication number
KR20230121831A
KR20230121831A KR1020237023939A KR20237023939A KR20230121831A KR 20230121831 A KR20230121831 A KR 20230121831A KR 1020237023939 A KR1020237023939 A KR 1020237023939A KR 20237023939 A KR20237023939 A KR 20237023939A KR 20230121831 A KR20230121831 A KR 20230121831A
Authority
KR
South Korea
Prior art keywords
antibody
seq
antigen
binding fragment
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237023939A
Other languages
English (en)
Korean (ko)
Inventor
엘마 쿠르타직
제임스 더블유. 미도르 3세
크리스토퍼 베네두스
Original Assignee
모멘타 파머슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모멘타 파머슈티컬스 인코포레이티드 filed Critical 모멘타 파머슈티컬스 인코포레이티드
Publication of KR20230121831A publication Critical patent/KR20230121831A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237023939A 2020-12-18 2021-12-17 인테그린 알파 11 베타 1에 대한 항체 Pending KR20230121831A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063127849P 2020-12-18 2020-12-18
US63/127,849 2020-12-18
US202163213973P 2021-06-23 2021-06-23
US63/213,973 2021-06-23
PCT/IB2021/061926 WO2022130318A2 (en) 2020-12-18 2021-12-17 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
KR20230121831A true KR20230121831A (ko) 2023-08-21

Family

ID=79021748

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023939A Pending KR20230121831A (ko) 2020-12-18 2021-12-17 인테그린 알파 11 베타 1에 대한 항체

Country Status (13)

Country Link
US (1) US20240317865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263605A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024505790A (cg-RX-API-DMAC7.html)
KR (1) KR20230121831A (cg-RX-API-DMAC7.html)
AU (1) AU2021400221A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023011777A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205574A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001757A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008544A2 (cg-RX-API-DMAC7.html)
IL (1) IL303741A (cg-RX-API-DMAC7.html)
MX (1) MX2023007302A (cg-RX-API-DMAC7.html)
TW (1) TW202241946A (cg-RX-API-DMAC7.html)
WO (1) WO2022130318A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551471A1 (en) 2019-12-20 2023-04-24 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 beta 1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
US20230065153A1 (en) * 2018-03-01 2023-03-02 Hiroshima University Anti-integrin alpha-11 monoclonal antibody and use thereof
PH12022551471A1 (en) * 2019-12-20 2023-04-24 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 beta 1

Also Published As

Publication number Publication date
AU2021400221A1 (en) 2023-07-13
CA3205574A1 (en) 2022-06-23
US20240317865A1 (en) 2024-09-26
MX2023007302A (es) 2023-09-04
CL2023001757A1 (es) 2024-01-05
TW202241946A (zh) 2022-11-01
IL303741A (en) 2023-08-01
AU2021400221A9 (en) 2025-03-13
WO2022130318A2 (en) 2022-06-23
EP4263605A2 (en) 2023-10-25
BR112023011777A2 (pt) 2023-10-03
JP2024505790A (ja) 2024-02-08
WO2022130318A3 (en) 2022-08-04
CO2023008544A2 (es) 2023-07-10

Similar Documents

Publication Publication Date Title
JP7701911B2 (ja) Ceacam5およびcd3に対する二特異性抗体
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
KR102550991B1 (ko) 아밀로이드 베타에 대한 항체
TW201018483A (en) Novel anti CXCR4 antibodies and their use for the treatment of cancer
KR20210029158A (ko) Ceacam5 및 cd47에 대한 이중특이성 항체
TWI878554B (zh) 結合tnfr2的抗體及其用途
US20260042845A1 (en) Antibodies against integrin alpha 11 beta 1
AU2020390028A1 (en) Pharmaceutical composition, preparation method therefor and use thereof
US12600784B2 (en) Anti-Clec12A antibodies and uses thereof
CN116284426A (zh) 一种抗gucy2c/cd3双特异性抗体及其用途
US20240317865A1 (en) Antibodies against integrin alpha 11 beta 1
CN117222666A (zh) 抗整联蛋白α11β1抗体
JP7769635B2 (ja) 抗cd19抗体及びその使用
RU2827106C1 (ru) Биспецифические антитела против ceacam5 и cd3
EA048635B1 (ru) Антитела против интегрина альфа 11 бета 1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230713

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241213

Comment text: Request for Examination of Application